Linked Life Data

18687166

Source:http://linkedlifedata.com/resource/pubmed/id/18687166

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2008-9-24
pubmed:abstractText
Aliskiren, an antihypertensive drug approved in the United States and Europe, is the first in a new class known as direct renin inhibitors. Aliskiren has been evaluated for safety and tolerability in more than 6400 patients. It has demonstrated a favorable safety and tolerability profile alone or in combination with other drugs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1473-4877
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2627-37
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren.
pubmed:affiliation
Baylor College of Medicine, Texas Heart Institute, St Luke's Episcopal Hospital, Houston, TX 77030, USA. haroonur.rashid@kelsery-seybold.com
pubmed:publicationType
Journal Article, Review